Galectin-3 and heart failure: prognosis, prediction & clinical utility.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Clinica chimica acta; international journal of clinical chemistry

• Publication date

  2015-03-30

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.cca.2014.10.009PMID 25446877
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The role of glycemia in acute heart failure patients

  2014cited by this paper
• Clinical Risk Stratification Optimizes Value of Biomarkers to Predict New-Onset Heart Failure in a Community-Based Cohort

  2014cited by this paper
• Comparative study of galectin-3 and B-type natriuretic peptide as biomarkers for the diagnosis of heart failure

  2014cited by this paper
• Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure.

  2014cited by this paper
• Osteopontin and Galectin‐3 Predict the Risk of Ventricular Tachycardia and Fibrillation in Heart Failure Patients with Implantable Defibrillators

  2014cited by this paper
• Practical experience using galectin-3 in heart failure

  2014cited by this paper
• Renal Handling of Galectin‐3 in the General Population, Chronic Heart Failure, and Hemodialysis

  2014cited by this paper
• Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION.

  2014cited by this paper
• Emergency department use of galectin-3.

  2014cited by this paper
• Plasma galectin 3 and heart failure risk in the Physicians' Health Study

  2014cited by this paper
• The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure

  2014cited by this paper
• Structural myocardial alterations in diabetes and hypertension: the role of galectin-3

  2014cited by this paper
• Galectin-3 testing: validity of a novel automated assay in heart failure patients with reduced ejection fraction.

  2014cited by this paper
• Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials.

  2014cited by this paper
• Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.

  2014cited by this paper
• Usefulness of Combining Galectin-3 and BIVA Assessments in Predicting Short- and Long-Term Events in Patients Admitted for Acute Heart Failure

  2014cited by this paper
• Galectin 3 and incident atrial fibrillation in the community.

  2014cited by this paper
• Galectin-3 expression in cardiac remodeling after myocardial infarction.

  2014cited by this paper
• Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study.

  2014cited by this paper
• Using Biomarkers to “Guide” Heart Failure Management: Current Perspectives and Future Directions

  2013cited by this paper
• Elevated galectin-3 precedes the development of CKD.

  2013cited by this paper
• Forecasting the Impact of Heart Failure in the United States: A Policy Statement From the American Heart Association

  2013cited by this paper
• Galectin-3 Mediates Aldosterone-Induced Vascular Fibrosis

  2013cited by this paper
• Galectin-3 and Cardiac Function in Survivors of Acute Myocardial Infarction

  2013cited by this paper
• Genetic and Pharmacological Inhibition of Galectin-3 Prevents Cardiac Remodeling by Interfering With Myocardial Fibrogenesis

  2013cited by this paper
• Serial measurement of galectin‐3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study

  2013cited by this paper
• Galectin‐3 in heart failure with preserved ejection fraction

  2013cited by this paper
• Is hospital admission for heart failure really necessary?: the role of the emergency department and observation unit in preventing hospitalization and rehospitalization.

  2013cited by this paper
• Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure

  2013cited by this paper
• Prognostic Value of Changes in Galectin-3 Levels Over Time in Patients With Heart Failure: Data From CORONA and COACH

  2013cited by this paper
• Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction.

  2013cited by this paper
• 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2013cited by this paper
• EURObservational Research Programme: regional differences and 1‐year follow‐up results of the Heart Failure Pilot Survey (ESC‐HF Pilot)

  2013cited by this paper
• The association between galectin-3 and clinical parameters in patients with first acute myocardial infarction treated with primary percutaneous coronary angioplasty.

  2013cited by this paper
• Baseline and serial measurements of galectin‐3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val‐HeFT

  2013cited by this paper
• Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results.

  2013cited by this paper
• Galectin 3 complements BNP in risk stratification in acute heart failure

  2012cited by this paper
• Galectin-3 in Ambulatory Patients With Heart FailureClinical Perspective

  2012cited by this paper
• Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community.

  2012cited by this paper
• Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3.

  2012cited by this paper
• ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012

  2012cited by this paper
• Recent advances in the management of chronic heart failure

  2012cited by this paper
• Galectin-3 in Ambulatory Patients With Heart Failure: Results From the HF-ACTION Study

  2012cited by this paper
• Use of biomarkers to guide outpatient therapy of heart failure

  2012cited by this paper
• The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).

  2012cited by this paper
• Multimarker strategy for short-term risk assessment in patients with dyspnea in the emergency department: the MARKED (Multi mARKer Emergency Dyspnea)-risk score.

  2012cited by this paper
• Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22.

  2012cited by this paper
• Aging of the United States Population: Impact on Heart Failure

  2012cited by this paper
• Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival.

  2011cited by this paper
• Modified Citrus Pectin Reduces Galectin-3 Expression and Disease Severity in Experimental Acute Kidney Injury

  2011cited by this paper
• Roberto Martínez Martínez

  2011cited by this paper
• Prognostic value of galectin-3, a novel marker of fibrosis

  2010cited by this paper
• Heart disease and stroke statistics--2010 update: a report from the American Heart Association.

  2010cited by this paper
• Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association.

  2010cited by this paper
• Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction

  2010cited by this paper
• Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study

  2010cited by this paper
• N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study.

  2010cited by this paper
• Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure.

  2010cited by this paper
• The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients.

  2009cited by this paper
• N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin.

  2009cited by this paper
• Galectin‐3: a novel mediator of heart failure development and progression

  2009cited by this paper
• The regulation of inflammation by galectin‐3

  2009cited by this paper
• Heart failure: the commonest reason for hospital admission in Germany: medical and economic perspectives.

  2009cited by this paper
• Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis.

  2008cited by this paper
• ECM remodeling in hypertensive heart disease.

  2007cited by this paper
• Galectin-3 regulates myofibroblast activation and hepatic fibrosis.

  2006cited by this paper
• Galectin-3: an open-ended story.

  2006cited by this paper
• Congestion in acute heart failure syndromes: an essential target of evaluation and treatment.

  2006cited by this paper
• EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population.

  2006cited by this paper
• Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure.

  2006cited by this paper
• Galectins as modulators of tumour progression

  2005cited by this paper
• Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology.

  2005cited by this paper
• Obesity and suppressed B-type natriuretic peptide levels in heart failure.

  2004cited by this paper
• Impact of Obesity on Plasma Natriuretic Peptide Levels

  2004cited by this paper
• Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac Dysfunction

  2004cited by this paper
• Expression of galectins in cancer: A critical review

  2004cited by this paper
• B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study.

  2003cited by this paper
• Lifetime Risk for Developing Congestive Heart Failure: The Framingham Heart Study

  2002cited by this paper
• Galectins and cancer.

  2002cited by this paper
• Epidemiology, aetiology, and prognosis of heart failure

  2000cited by this paper
• Mapping of the galectin-3 gene (LGALS3) to human Chromosome 14 at region 14q21-22

  1997cited by this paper
• Expression and function of galectin-3, a beta-galactoside-binding lectin, in human monocytes and macrophages.

  1995cited by this paper

• Tracing the Rise of Galectin-3: A Global Bibliometric Insight Into Its Role in Heart Failure

  2025cites this paper
• Cardiovascular Biomarkers: Tools for Precision Diagnosis and Prognosis

  2025cites this paper
• Frequency of Heart Failure in Patients Thrombolysed for Acute Interior Wall Myocardial Infarction

  2025cites this paper
• Galectin-3 and Strain Imaging for Early Heart Failure Prediction After First Myocardial Infarction

  2025cites this paper
• Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets

  2024cites this paper
• Role of galectin-3 as a biomarker in obstructive sleep apnea: a systematic review and meta-analysis

  2023cites this paper
• Global historical retrospect and future prospects on biomarkers of heart failure: A bibliometric analysis and science mapping

  2023cites this paper
• Fibrotic Marker Galectin-3 Identifies Males at Risk of Developing Cancer and Heart Failure

  2023cites this paper
• Risk prediction model construction for post myocardial infarction heart failure by blood immune B cells

  2023cites this paper
• Value of NT-proBNP and Galectin-3 as Biomarkers in the Follow-Up of Asymptomatic Elderly Patients with Severe Aortic Stenosis

  2023cites this paper
• Cardiac MRI may not detect myocardial ischemia and fibrosis in dogs with cardiomegaly secondary to myxomatous mitral valve disease.

  2022cites this paper
• Galectin-3 in cardiology

  2022cites this paper
• STUDYING THE SIMULTANEOUS EFFECT OF COMBINED EXERCISES AND SUPPLEMENTATION OF MULBERRY LEAF EXTRACT ON SOME INFLAMMATORY BIOMARKERS EFFECTIVE IN THE PATHOGENESIS OF DIABETES AND HBA1C IN ELDERLY MEN WITH TYPE 2 DIABETES

  2022cites this paper
• Utility of cardiac MRI to diagnose myocardial ischemia and fibrosis in dogs with cardiomegaly secondary to myxomatous mitral valve disease

  2022cites this paper
• Frequency of acute heart failure in patients undergoing thrombolysis for anterior wall myocardial infarction.

  2022cites this paper
• High and Moderate Intensity Aerobic Training Effects on Galectin-3, Pentraxin-3, and Several Inflammatory Mediators Levels in Type 2 Diabetic Women, a Randomized Clinical Trial

  2021cites this paper
• Lifestyle in Female Teachers: Educational Intervention Based on Self-Efficacy Theory in the South of Fars Province, Iran

  2021cites this paper
• Кардиопротективные механизмы ингибиторов натрий-глюкозного котранспортера 2 типа

  2021cites this paper
• Galectin-3 as a Predictor for Left Ventricular Remodeling After Anterior Wall Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention

  2021cites this paper
• The role of fibrosis biomarkers in predicting the development of myocardial electrical instability (a literature review)

  2021cites this paper
• Роль біомаркерів фіброзу у прогнозуванні розвитку електричної нестабільності міокарда (огляд літератури)

  2021cites this paper
• Galectin-3 and neutrophil-to-lymphocyte ratio are indicative of heart remodelling and disease severity in patients with obstructive sleep apnoea.

  2021cites this paper
• Galectina-3 Associada a Formas Graves e Mortalidade em Longo Prazo em Pacientes com Doença de Chagas

  2021cites this paper
• Galectina-3 em Pacientes com Pericardite Constritiva Crônica

  2020influential citation
• UMBRELLA protocol: systematic reviews of multivariable biomarker prognostic models developed to predict clinical outcomes in patients with heart failure

  2020cites this paper
• Aortic valve calcification in the era of non-coding RNAs: The revolution to come in aortic stenosis management?

  2020cites this paper
• Value of Galectin-3 assay in children with heart failure secondary to congenital heart diseases: a prospective study

  2020cites this paper
• Galectin-3 and Risk of Late Graft Failure in Kidney Transplant Recipients: A 10-year Prospective Cohort Study

  2020cites this paper
• Cardiac fibrosis.

  2020cites this paper
• Galectin-3 Plasma Levels Are Associated with Risk Profiles in Pulmonary Arterial Hypertension

  2020cites this paper
• Galectin-3, N-terminal Propeptides of Type I and III Procollagen in Patients with Atrial Fibrillation and Metabolic Syndrome

  2020cites this paper
• Galactin-3 and soluble ST2 as complementary tools to cardiac MRI for sudden cardiac death risk stratification in heart failure: A review

  2020cites this paper
• GALECTIN-3 , MMP-9 AND ST2 : BIOCHEMICAL MARKERS IN CARDIOVASCULAR DISEASES

  2019influential citation
• Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities.

  2019cites this paper
• Galectin-3 is involved in HIV-1 expression through NF-κB activation and associated with Tat in latently infected cells.

  2019cites this paper
• Sleep apnea and galectin-3: possible sex-specific relationship

  2019cites this paper
• Cardiac Injury, Maladaptation, and Heart Failure Incidence

  2019cites this paper
• Stimulation of β‐adrenoceptors up‐regulates cardiac expression of galectin‐3 and BIM through the Hippo signalling pathway

  2019cites this paper
• Galectin‐3 aggravates ox‐LDL‐induced endothelial dysfunction through LOX‐1 mediated signaling pathway

  2019cites this paper
• The effect of an educational program based on Roy's adaptation model on the quality of life of patients suffering from heart failure: A clinical trial study.

  2019cites this paper
• sST2 adds to the prognostic value of Gal-3 and BNP in chronic heart failure

  2019cites this paper
• Galectin-3 in children with heart failure secondary to congenital heart diseases

  2019cites this paper
• Galectin-3 in patients with coronary heart disease and atrial fibrillation.

  2018cites this paper
• Possible Role of Inflammation and Galectin-3 in Brain Injury after Subarachnoid Hemorrhage

  2018cites this paper
• The Relationship Between Quality of Life and Cardiovascular Self-Efficacy in Patients with Heart Failure: A Descriptive Correlation Study

  2018cites this paper
• Evaluation of Galectin-3 and Myocardial Fibrosis in Patients with Hypertrophic Cardiomyopathy

  2018cites this paper
• Plasma levels of heart failure biomarkers are primarily a reflection of extracardiac production

  2018cites this paper
• Galectin-3 as a novel biomarker in women with PCOS

  2018cites this paper
• Novel heart failure biomarkers: why do we fail to exploit their potential?

  2018cites this paper
• Establishing reference intervals for galectin-3 concentrations in serum requires careful consideration of its biological determinants.

  2017cites this paper
• Blood, tissue and imaging biomarkers in calcific aortic valve stenosis: past, present and future

  2017cites this paper
• Chapter 5 Galectin-3 and Post-Myocardial Infarction Cardiac Remodeling

  2017cites this paper
• Effects of a cardiac rehabilitation programme on plasma cardiac biomarkers in patients with chronic heart failure

  2017cites this paper
• Preliminary profiling of blood transcriptome in a rat model of hemorrhagic shock

  2017cites this paper
• Functions of galectins as ‘self/non‐self’‐recognition and effector factors

  2017cites this paper
• Increased galectin-3 levels are associated with abdominal aortic aneurysm progression and inhibition of galectin-3 decreases elastase-induced AAA development.

  2017cites this paper
• Galectin-3 in Children with Chronic Heart Failure with Normal and Reduced Ejection Fraction: Relationship to Disease Severity

  2016cites this paper
• The World is Changing – Are We Ready ? ST 2 and galectin-3 : ready for prime time ?

  2016cites this paper
• ST2 and Galectin-3: Ready for Prime Time?

  2016cites this paper
• Du BNP au ST2 : quels biomarqueurs utiliser en pratique?

  2016cites this paper
• RhoGTPases and their relevance for the afterload-dependent myocardial fibrosis

  2016cites this paper
• Characteristics and outcomes of acute heart failure in sub Saharan Africa

  2016cites this paper
• The Status of Quality of Life and Adaptation of Patients with Heart Failure to Their Disease in Shushtar, Khuzestan Province

  2016cites this paper
• High GAL-3 may be Associated with Higher Age and Low Levels of Chloride, RDW, and MCHC in Heart Failure

  2016cites this paper
• Potential novel biomarkers of cardiovascular dysfunction and disease: cardiotrophin-1, adipokines and galectin-3

  2016cites this paper
• Predictive Value for Galectin 3 and Cardiotrophin 1 in Hemodialysis Patients

  2016cites this paper
• The predictive value of plasma biomarkers in discharged heart failure patients: role of galectin-3.

  2016cites this paper
• Authors' Reply.

  2016cites this paper
• Circulating Galectin-3 Levels Are Increased in Patients with Ischemic Heart Disease, but Are Not Influenced by Acute Myocardial Infarction

  2016cites this paper
• Galectin-3, osteopontin and successful aging

  2016cites this paper
• [From BNP to ST2: Which biomarkers to use in practice?]

  2016cites this paper
• The role of Galectin-3 in cardiac remodeling

  2016cites this paper
• Determinants and prognostic value of Galectin-3 in patients with aortic valve stenosis

  2016cites this paper
• [ANMCO/ELAS/SIBioC Consensus document: Recommendations for the use of cardiac biomarkers in heart failure patients].

  2016cites this paper
• Galectin-3 and post-myocardial infarction cardiac remodeling.

  2015cites this paper
• Prognostic values of cardiac biomarkers screening in dialysis patients

  2015cites this paper
• Pathogenesis and clinical presentation of acute heart failure.

  2015cites this paper
• Patogenia y presentación clínica de la insuficiencia cardiaca aguda

  2015cites this paper
• Biomarkers in heart failure.

  2015cites this paper
• Extracellular galectin-3 programs multidrug resistance through Na+/K+-ATPase and P-glycoprotein signaling

  2015cites this paper
• Galectin-3 in atrial fibrillation: Simple bystander, player or both?

  2015cites this paper
• Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction.

  2015cites this paper